Experimental findings reveal a 4-atom linker enhances biological activity in PROTACs, indicating potential for drug development.
Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional molecules, emerging as a promising class of drugs.Amongst their structural components, the linker moiety plays a pivotal role in modulating their biological activity and...
No takes yet. Share an insight, caveat, or question.
Letsios et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: